SingVax Merges With Inviragen To Raise $15 Million In Series-A Financing For Vaccines To Fight Infectious Disease

SINGAPORE - U.S.-based Inviragen and Singapore-based SingVax unveiled plans to merge their companies' vaccine pipelines to form a new entity known as Inviragen (Singapore) to develop vaccines for a range of infectious diseases including dengue fever, Japanese encephalitis and hand, foot and mouth disease